During the GvHD Hub Steering Committee Meeting in July 2026, key opinion leaders met to discuss how extracorporeal photophoresis (ECP) is used in clinical practice for the treatment of pediatric graft-versus-host disease (GvHD), including benefits and challenges associated with its use. The meeting opened with a presentation from Andrew Harris, and featured a panel discussion with Mohamad Mohty, Corey Cutler, Hildegard Greinix, and Daniel Wolff.
During his presentation, Harris explained that, beyond first-line steroid therapy, the management of GvHD relies on a range of second-line treatment options, noting there are limited data and guidance specific to pediatric patients. Among these, ECP – an immunomodulatory leukapheresis-based therapy – is increasingly being incorporated into clinical practice as a second-line or later treatment. However, its use in pediatric patients remains variable, with no standardized approach. Harris presented a case from his practice involving a 3-year-old patient who developed acute GvHD following transplantation and was treated with ECP. He also discussed the practical and logistical considerations associated with ECP and explored how micro-ECP may overcome some of the challenges limiting ECP use in pediatric patients.
This educational activity is independently supported by Therakos. All content is developed by the steering committee in collaboration with SES. Funders are allowed no influence
","author_name":"Scientific Education Support"}